RxLink Pharmacy Services

RxLink - Spirit of the Independent Pharmacist!

Pharmacy News

June 2007 - EXFORGE from Novartis

HMO News

Events for Pharmacists

Clinical Pharmacy

Compounding Pharmacy

HomeCare Pharmacy

Long-Term Care 

RxLink Nutrition


Pharmacy Staffing

Pharmacy Affiliates

Independent Voices

E-mail us

Feedback to RxLink

HealthCare Services


June 2003 

To RxLink From: ETHEX, the nation's leading provider of prescription prenatal vitamins*, is pleased to provide the enclosed prenatal vitamin reference materials, designed to help you determine which ETHEX prenatal vitamin to use.

Remove the ETHEX Born to Lead cross-reference static cling sheet from the paper backing and post it on any surface in your pharmacy. Consult the ingredient comparison chart whenever there are questions about the active ingredients in any ETHEX prenatal vitamin.

To automatically receive updated reference materials whenever there are changes to ETHEX's prenatal vitamin family, contact ETHEX by phone at 1-800-321-1705 or by email at info@ethex.com.

Thank you for dispensing ETHEX prenatal vitamins!

Brook Eiler
Product Manager

*IMS America, Units MAT, February 2003.



As a demonstration of our ongoing commitment to excellence in customer service, Apotex Corp. is pleased to announce that Capital Returns has been selected as our return goods processing agent.  Effective July 1, 2004 all Apotex Corp. returns for expired and short-dated product should be sent to Capital Returns, Inc at the following address:

          Capital Returns, Inc.                                                                CapOne Return Program                                                              4066 North Port Washington Road                                           Milwaukee, WI 53212                                                                   Phone: 800-950-5479

All returns will be processed in accordance with updated Apotex Corp's Return Goods Policy,  Our updated policy can be found here.  Please review the policy in detail and update your records accordingly as changes have been made.

Capital Return's Customer Service Team is available for any questions that you may have on how to return the product.  In ordeer to avoid any delays in the processing of your returns, please make sure to include the following information with your return: your complete company name and address, your wholesaler name and address (if applicable), debit memo number and current DEA number and expiration date.

Should you have any questions regarding the status of a return, please call Capital Returns, Inc at 800-950-5479.

Thank you for your valued business.


Source: Apotex Corp


From: GlaxoSmithKline

August 2007

Important Prescribing Information

GlaxoSmithKline (GSK) is fully committed to the timely communication of safety information about its products to the healthcare community. In collaboration with the U.S. Food and Drug Administration, we are updating the rosiglitazone prescribing information with regard to heart failure.  This labeling affects rosiglitazone-containing products, i.e. Avandia® (rosiglitazone maleate) tablets, Avandamet (rosiglitazone maleate and metformin hydrocloride) tablets, and Avandaryl (rosiglitazone maleate and glimeperide) Tablets, which are used in treating type 2 diabetes melitus.

Important changes to the Prescribing Information for Avandia, Avandamet and Avandaryl include:

1. Boxed warning regarding heart failure...

2. Contraindication for initiation of rosiglitazone in patients with NYHA class III and IV heart failure.


. Thiazolidinediones, including rosiglitazone, cuase or exacerbate congestive heart failure in some patients. After initiation of Avandia, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and / or edema).  If these symptoms develop, the heart failure should be managed according to current standards of care.  Futhermore, discontinuation or dose reduction of AVANDIA must be considered.

. AVANDIA is not recommended in patients with symptomatic heart failure. Initiation of AVANDIA in patients with establised NYHA Class III or Class  IV heart failure is contraindicated.



RxLink LLC  RxLink Pharmacy Franchise Services © 1993 - 2016 All Rights Reserved